1,353 results on '"Behr, Jürgen"'
Search Results
102. Treatment strategies and survival of patients with connective tissue disease and pulmonary arterial hypertension: A COMPERA analysis
103. Antiviral CD8+T-cell immune responses are impaired by cigarette smoke and in COPD
104. Cytokine signaling converging on IL11 in ILD fibroblasts provokes aberrant epithelial differentiation signatures
105. The art of clinical trial design in pulmonary fibrosis
106. „Nicht schon wieder ein Pneumothorax“ – Fallbericht Birt-Hogg-Dubé-Syndrom
107. Riociguat for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Results from a phase II long-term extension study
108. Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy?
109. Variability of forced vital capacity in progressive interstitial lung disease: a prospective observational study
110. Radiation-induced lung toxicity – cellular and molecular mechanisms of pathogenesis, management, and literature review
111. Differential response to biologics in a patient with severe asthma and ABPA: a role for dupilumab?
112. Targeted metabolomics of pellicle and saliva in children with different caries activity
113. Hyperinflation and reduced diffusing capacity predict prognosis in SCLC: value of extended pre-therapeutic lung function testing.
114. Letermovir for Difficult to Treat Cytomegalovirus Infection in Lung Transplant Recipients
115. Rating of the industrial application potential of yeast strains by molecular characterization
116. Idiopathic Pulmonary Fibrosis Among Young Patients: Challenges in Diagnosis and Management
117. Ambrisentan ± tadalafil in WHO functional class II/III pulmonary arterial hypertension: a guide to its use in the EU
118. Interstitielle Lungenerkrankungen: Was muss der Hausarzt wissen?
119. Interspecies Comparison of Rat and Hamster Alveolar Macrophage Antioxidative and Oxidative Capacity
120. Zunehmende Luftnot und wechselnde Gelenkbeschwerden
121. SARS-CoV-2-Infektion und interstitielle Lungenerkrankungen – Positionspapier der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin
122. High in-hospital mortality in SARS-CoV-2 infected patients with active cancer disease during Omicron phase of the pandemic – Insights from the CORONA Germany Study
123. Phosphoproteomics of cellular mechanosensing reveals NFATC4 as a regulator of myofibroblast activity
124. Erratum: Pharmakotherapie der idiopathischen Lungenfibrose (ein Update) und anderer progredienter pulmonaler Fibrosen
125. Pharmakotherapie der idiopathischen Lungenfibrose (ein Update) und anderer progredienter pulmonaler Fibrosen
126. Validation of disease-specific biomarkers for the early detection of bronchopulmonary dysplasia
127. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: a randomised, double-blind, placebo-controlled, phase 2 trial
128. Approach to the Diagnosis of Interstitial Lung Disease
129. Contributors
130. Proteasome activator PA200 regulates myofibroblast differentiation
131. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry
132. Das virtuelle ILD-Board – Erfahrungen aus einem Pilotprojekt.
133. Comparison of the sensitivity of different criteria to select lung cancer patients for screening in a cohort of German patients
134. Ex vivotissue perturbations coupled to single cell RNA-seq reveal multi-lineage cell circuit dynamics in human lung fibrogenesis
135. Quantitative proteomics of differentiated primary bronchial epithelial cells from chronic obstructive pulmonary disease and control identifies potential novel host factors post-influenza A virus infection
136. Standardized airway wall thickness Pi10 from routine CT scans of COPD patients as imaging biomarker for disease severity, lung function decline, and mortality
137. Cytokine signaling converging onIL11in ILD fibroblasts provokes aberrant epithelial differentiation signatures
138. Was haben wir aus der deutschen COPD-Kohorte COSYCONET gelernt und wie geht es weiter?
139. A Phase IIb Randomized Clinical Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis
140. Investigating significant health trends in progressive fibrosing interstitial lung disease (INSIGHTS-ILD) : Rationale, aims and design of a nationwide prospective registry
141. Erratum : Pharmakotherapie der idiopathischen Lungenfibrose (ein Update) und anderer progredienter pulmonaler Fibrosen
142. Consensus guideline on the interdisciplinary diagnosis of interstitial lung diseases
143. sj-pdf-1-tar-10.1177_17534666221148663 – Supplemental material for Standardized airway wall thickness Pi10 from routine CT scans of COPD patients as imaging biomarker for disease severity, lung function decline, and mortality
144. Pharmakotherapie der idiopathischen Lungenfibrose (ein Update) und anderer progredienter pulmonaler Fibrosen : S2k-Leitline der Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin e. V
145. SARS-CoV-2-Infection and Interstitial Lung Disease : Position paper of the German Respiratory Society
146. sj-docx-2-tar-10.1177_17534666221148663 – Supplemental material for Standardized airway wall thickness Pi10 from routine CT scans of COPD patients as imaging biomarker for disease severity, lung function decline, and mortality
147. Boosting the growth of the probiotic strain Lactobacillus paracasei ssp. paracasei F19
148. Acute effects of riociguat in borderline or manifest pulmonary hypertension associated with chronic obstructive pulmonary disease
149. Phenotypical and molecular characterization of yeast content in the starter of “Tchoukoutou,” a Beninese African sorghum beer
150. Einsatz antifibrotischer Medikamente bei interstitiellen Lungenerkrankungen
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.